CUPERTINO, Calif., June 29, 2015 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 8 at 11:45 a.m. Eastern Time. The conference is being held at Le Parker Meridien Hotel in New York City. Investors and analysts that are attending the conference may request a one-on-one meeting through the conference organizers at http://www.cantorconferences.com/health-registration/health-investors
A live audio webcast of the presentation will be available by accessing http://wsw.com/webcast/cantor2/drrx.
A live audio webcast of the presentation will also be available by accessing DURECT’s homepage at www.www.durect.com and clicking “Investor Relations.”
If you are unable to participate during the live webcast, the call will be archived on DURECT’s website under Audio Archive in the “Investor Relations” section.
About DURECT Corporation
DURECT is an innovative biopharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, CNS disorders, acute organ injury and metabolic diseases. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. Late stage development programs of this nature include POSIDUR™ and REMOXY®. DURECT’s Epigenomic Regulator Program includes the lead molecule DUR-928 in Phase 1 clinical testing. DUR-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. For more information, please visit www.www.durect.com.
NOTE: POSIDUR™ is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective owners. POSIDUR, REMOXY and DUR-928 are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/durect-to-present-at-the-cantor-fitzgerald-healthcare-conference-300106295.html
SOURCE DURECT Corporation
Matthew J. Hogan, Chief Financial Officer, DURECT, 408-777-4936